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HIV infects millions of people worldwide; however, no
cures for this AIDS-causing retrovirus exist. A new ap-
proach using trans-platinum-nucleobase complexes
to inhibit viral replication by disrupting the nucleocap-
sid protein-RNA interaction is presented in this issue
of Chemistry & Biology [1].
Every student of bioinorganic chemistry is familiar with
the discovery and chemistry of platinum anticancer
drugs. The success of cisplatin in treating cancer estab-
lished an important paradigm for the potential of drug
discovery at the interface of inorganic chemistry and bi-
ology [2]. Over 40 years ago, Barnett Rosenburg and
coworkers discovered that platinum complexes had
the unique ability to inhibit the mitosis of bacteria [3],
and shortly afterwards they reported the antitumor
activity of cisplatin (cis-diaminedichloroplatinum(II) or
cis-DDP) [4]. Since the FDA approved cisplatin in 1978,
cases of testicular cancer that were once fatal have
been cured with a >90% success rate. This clinical
success has pushed cisplatin to the forefront of metal-
based chemotherapies used today. A number of cis-
platin analogs have been reported, but only a select
few like carboplatin have found utility in cancer treat-
ment [5]. One seminal observation from the early studies
was that the geometrical isomer trans-DDP is ineffective
in treating tumors (Figure 1). As thalidomide established
the importance of enantiomeric purity for the activity of
organic drugs, cisplatin demonstrated importance of
structure-function relationships in inorganic pharma-
ceuticals.
The oft-repeated pronouncement of trans-isomer in-
activity has proven to be only partially accurate as plat-
inum research has matured over the last 15 years. The
nature of the DNA crosslinks formed [6] and the recogni-
tion of these adducts by proteins [7] are major factors
that prevent trans-DDP from exhibiting anticancer prop-
erties; however, after studying some simple structural
modifications, active trans-platinum complexes have
been discovered. Inclusion of alkyl amine [8], pyridine
[9], iminoether [10], or photoactive ligands [11], as well
as using linked platinum complexes [12], provides po-
tential anticancer agents, including several that exhibit
activity against cisplatin-resistant tumors. These and
other investigations have focused on approaches to en-
hance the cytotoxicity of trans-complexes by using the
trans-geometry to take advantage of unique interactions
between the platinum, DNA, and proteins inaccessible
to the cis-isomer.
Because of the success of cisplatin, most research on
trans-platinum complexes has concentrated on devel-
oping new cancer treatments; however, Farrell and
coworkers have developed a strategy to utilize these
complexes to target and treat HIV [1]. These trans-
configured compounds target the zinc fingers foundon retroviral nucleocapsid proteins by taking advantage
of noncovalent interactions and the trans- geometry of
the complex to orient the platinum for an attack on
a zinc finger ‘‘knuckle’’ sequence. Binding of the trans-
platinum complex initiates a cascade of reactions that
ultimately results in removal of a Zn2+ ion from the finger
motif, leading to loss of the protein’s tertiary structure
(see Figure 7B in [1]).
Farrell and coworkers first hypothesized that
platinum-nucleobases might be attractive targets for
antiviral agents based on their discovery that a quinoline
derivative had some ability to remove Zn2+ from nucleo-
capsid proteins [13]. Subsequent efforts attempted to
promote and enhance noncovalent recognition between
proteins and nucleobases by platination [14] and to
elucidate the mechanism of Zn2+ removal using model
complexes [15]. The most recent work brings all these
concepts together in a comprehensive study to develop
an antiviral platinum drug candidate. With [PtCl(9-EtGH)
(pyr)2] (EtGH = 9-ethylguanine), a noncovalent p-stack-
ing interaction between the platinated guanine and
a tryptophan residue in a peptide derived from the
C-terminal zinc knuckle of the HIV nucleocapsid protein,
NCp7, provides the first step in a proposed antiviral
mechanism. This interaction positions the complex for
electrophilic attack on a Zn bound cysteine, which is
part of a structural zinc finger. After the cysteine thiol
displaces the labile chloride ligand, a second cysteine
thiol from the zinc finger motif displaces the nucleobase,
ejecting the Zn2+ in the process, to give a platinum com-
plex with trans-pyridine and trans-cysteine ligands. This
series of changes in the tertiary structure renders the
nucleocapsid protein incapable of binding with RNA,
which could thereby prevent viral replication.
Despite the difference in disease targets for cisplatin
and Farrell’s trans-nucleobase complexes, some paral-
lels in the two systems are immediately apparent and
illustrate important fundamental principles of the rela-
tionship between biological and inorganic chemistry.
Binding of proteins like high mobility group 1 (HMG1)
to cisplatin-modified DNA has been identified as an
important feature in the antitumor activity of the metal
complex [16]. The crystal structure of the cis-[Pt(NH3)2]
d(GpG) intrastrand crosslink revealed that bending and
unwinding of the DNA duplex created a hydrophobic
notch into which a phenylalanine residue of HMG1 is
intercalated [17]. Platinum binding predisposes the
aromatic ring of the guanosine base to p-stack with
the phenylalanine group [18] in a manner similar to the
Figure 1. The Structures of cis- and trans-DDP
(A) cis-DDP; (B) trans-DDP. Only the cis-isomer is effective in treat-
ing cancer.
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466interaction observed between the tryptophan residue
and the guanine trans-platinum complexes in Farrell’s
work [1, 14] (Figure 2).
The comparison of cisplatin and the trans-nucleobase
compounds also extends to the ligand-exchange reac-
tions that play an intricate role in the interaction of plat-
inum with biomolecules. Once cisplatin enters the cell, it
loses a chloride ligand(s) to generate active aqua-plati-
num complexes; the soft nitrogen donors of nucleotide
bases subsequently displace the water ligands to form
various platinum-DNA adducts. The newly reported
antiviral trans-platinum complexes also are proposed
to undergo a series of ligand-exchange reactions before
the final platinum-modified protein is produced. One
essential feature is the labile chloride ligand that is
displaced by a Zn bound cysteine after the initial non-
Figure 2. Similar p-Stacking Interactions Are Key Features in the
Efficacy of Cisplatin as an Anticancer Drug and for the trans-
Platinum-Nucleobase Complex in Ejecting Zn2+ from Zinc Fingers
of Nucleocapsid Proteins
(A) For cisplatin (green), a phenylalanine (blue) of HMG1 stacks with
a platinum bound guanosine mediating the protein-DNA binding.
(B) For the trans-complex, the platinum bound guanine p-stacks
with a tryptophan residue.
Source: Figure 4A reprinted by permission from Macmillan Pub-
lishers Ltd: Nature [17], Copyright 1999.covalent recognition event in a manner analogous to
the nucleobase-water ligand exchange for cisplatin. In
the final complex, both the chloride and the nucleobase
ligand have been replaced by the softer cysteine donors
to give a new trans-platinum complex.
Some of the observed side effects of cisplatin treat-
ment stem from nonspecific interactions with proteins
and nucleic acids. These new trans-platinum com-
plexes also have the potential to participate in adventi-
tious binding events. However, the NCp7 target appears
to possess features that predispose the therapeutic ap-
proach for success. Although zinc finger motifs are
among the most widespread metal binding sites in biol-
ogy, the specific CCHC sequences found in the nucleo-
capsid proteins are quite rare [19]. In addition, both of
the capsid’s zinc finger domains must be intact to medi-
ate the protein’s interaction with RNA, so loss of a single
Zn2+ ion should be sufficient to inhibit viral replication.
The combination of these two factors suggests that
even if the trans-platinum-nucleobase complex exhibits
only moderately selective recognition of the dual zinc
finger domain, the complexes have great potential to
be effective therapeutic agents.
Several decades of research were required to trans-
form cisplatin from a simple coordination complex to
a universally accepted cancer therapy. With the excep-
tion of a few examples of inorganic pharmaceuticals,
transition metal complexes are less frequently screened
as drug candidates compared to organic molecules;
however, the cisplatin and now trans-platinum stories
illustrate the potential of metal-based therapeutics.
HIV/AIDS afflicts millions of people, particularly those
in the developing world where prevention proves diffi-
cult, so the need for a cure is critical. Perhaps this is
the beginning of a new chapter in the success story of
medicinal platinum chemistry: one that illustrates how
basic chemical research can yield unpredicted applica-
tions. None of the early cisplatin researchers who dis-
missed trans-DDP as an ineffective cancer drug could
have predicted that, one day, related compounds might
provide a treatment for another fatal disease.
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